Forkhead box O3 promotes colon cancer proliferation and drug resistance by activating MDR1 expression
Authors:
Open Access
- 8 January 2019
- journal article
- research article
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 7 (3) , e554
Abstract
Background: Globally, colon cancer (CC) is the third reason of tumor‐related deaths. Previous reports indicate that Forkhead box O3 (FOXO3) is involved in the development of various tumors and may have different effects depending upon the types of tumors. Hence, this study was to examine the effects of FOXO3 on CC cells and uncover the possible mechanisms.Methods: MTT and cell count assay were applied to analyze the viability of transfected CC cells. rVista, dual luciferase reporter assay, and chromatin immunoprecipitation assay were used to identify the downstream target of FOXO3 in HCT116 cells. The mRNA and protein abundance of FOXO3 and MDR1 were determined by quantitative PCR and Western blot, respectively.Results: Forkhead box O3 stimulated the proliferation of both HCT116 and DLD1 cells. Moreover, FOXO3 overexpression inhibited doxorubicin sensitivity of HCT116 cells, while the knockout of FOXO3 by FOXO3 shRNA restored the doxorubicin sensitivity in doxorubicin‐resistant HCT116 DR cells. Next, we found that FOXO3 directly bound to the promoter of MDR1 and enhanced MDR1 expression in HCT116 cells. MDR1 overexpression enhanced the viability and doxorubicin resistance of CC cells. Besides, MDR1 overexpression plasmid significantly abrogated the decrease in cell proliferation and resistance of HCT116 cells to doxorubicin caused by FOXO3 knockout.Conclusion: Forkhead box O3 exhibited promotive effects on the proliferation and doxorubicin resistance in CC cells via targeting MDR1.Keywords
Funding Information
- Key Research and Development Project of Shandong Province (2017GSF218068)
This publication has 25 references indexed in Scilit:
- IL-8 regulates the doxorubicin resistance of colorectal cancer cells via modulation of multidrug resistance 1 (MDR1)Cancer Chemotherapy and Pharmacology, 2018
- Independent prognostic genes and mechanism investigation for colon cancerBiological Research, 2018
- Safety data from the phase III Japanese ACHIEVE trial: part of an international, prospective, planned pooled analysis of six phase III trials comparing 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancerESMO Open, 2018
- Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myelomaLeukemia, 2017
- Role and regulation of the forkhead transcription factors FOXO3a and FOXM1 in carcinogenesis and drug resistanceChinese Journal of Cancer, 2013
- FOXO3 expression during colorectal cancer progression: biomarker potential reflects a tumour suppressor roleBritish Journal of Cancer, 2013
- Transient receptor potential channel TRPC5 is essential for P-glycoprotein induction in drug-resistant cancer cellsProceedings of the National Academy of Sciences, 2012
- The emerging roles of forkhead box (Fox) proteins in cancerNature Reviews Cancer, 2007
- Cell cycle and death control: long live ForkheadsTrends in Biochemical Sciences, 2002
- Establishment of doxorubicin-resistant subline derived from HCT15 human colorectal cancer cellsArchives of Pharmacal Research, 1996